@article{ref1,
title="Extended-release hydrocodone: the devil in disguise or just misunderstood?",
journal="Annals of pharmacotherapy",
year="2014",
author="Schweighardt, Anne E. and Juba, Katherine M.",
volume="48",
number="10",
pages="1362-1365",
abstract="Opioid abuse in the United States increased significantly over the past decade, leading to opioid-related deaths. Approval of Zohydro ER, a product that lacks an abuse-deterrent formulation, has provoked media controversy and aggressive legislative action from multiple stakeholders. Only the American Academy of Pain Management has released a position statement on this medication, and individual opinion varies. Additional single-entity extended-release hydrocodone formulations are in the pipeline, and Zohydro ER's limited clinical utility may make the controversy associated with its approval a moot point. As with other opioids, providers will need to assess individual patient risk versus benefit when prescribing Zohydro ER.  Keywords: Social Transition<p /> <p>Language: en</p>",
language="en",
issn="1060-0280",
doi="10.1177/1060028014543174",
url="http://dx.doi.org/10.1177/1060028014543174"
}